Message #20 From:
Stock News Bot Date: January 9, 2007 06:00:00 AM
CVBT News U.S. Patent Office Allows CVBT's Patent Application for the Injection of FGF-1 Into the Human Heart
LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that
the U.S. Patent and Trademark Office allowed CVBT’s
patent application entitled, “Method of
Producing Biologically Active Human Acidic Fibroblast Growth Factor and
its Use in Promoting Angiogenesis.” This
patent describes the technology to produce human Acidic Fibroblast
Growth Factor, also known as Fibroblast Growth Factor-1 (FGF-1), its
delivery via direct injection into the heart muscle, and the therapeutic
utility of this protein in the heart as an agent to stimulate new blood
vessel growth, a process called angiogenesis.
“The technology covered by this patent
involves the injection of our protein drug candidate directly into the
damaged heart muscle of patients suffering from coronary artery disease,”
stated Thomas J. Stegmann, M.D., Chief Medical Officer and Co-President
of CVBT. “As a cardiovascular surgeon, I
believe that this may be the most effective means to increase blood flow
into the heart muscle of patients afflicted with diffuse coronary artery
disease. Several previous clinical trials by others where the
therapeutic agent was administered into the coronary artery, or
delivered as a gene therapy treatment, appear to have failed because
they were either unsafe or did not meet their primary efficacy endpoints.”
Daniel Montano, Chief Executive Officer and Co-President of CVBT stated, “The
allowance of this patent provides CVBT with tremendous opportunity over
the next 12 years to effectively treat severe coronary artery disease.
We feel a growing body of evidence indicates that for angiogenesis
therapy in the heart to work optimally, the angiogenic agent must be a
protein, and that this protein should be injected directly into the
heart muscle, two critical points covered in our patent.”
Coronary heart disease, the most common form of cardiovascular disease,
is the number one cause of death in the U.S. and Europe. The disease
causes a reduction in blood flow that can result in chest pain, a heart
attack or death. According to the American Heart Association, 15.8
million Americans suffer from coronary heart disease.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing formulations of its
active pharmaceutical ingredient (API), Fibroblast Growth Factor-1, to
treat a number of diseases characterized by inadequate blood flow to a
tissue or organ. In addition to its cardiac clinical trial of FGF-1
(CVBT-141A) in Limited-Option Heart Patients, the Company is conducting
FDA-authorized clinical trials of FGF-1 (CVBT-141B) for dermal wound
healing in diabetics, and peripheral artery disease (CVBT-141C).
This news release contains forward-looking statements that involve risks
and uncertainties. Actual results and outcomes may differ materially
from those discussed or anticipated. For example, statements regarding
expectations for new research, progress with clinical trials or future
business initiatives are forward-looking statements. Factors that might
affect actual outcomes include, but are not limited to, results of
future clinical and pre-clinical trials, differences in patient
outcomes, FDA approval of CVBT drug candidates, market acceptance of
CVBT products by customers, new developments in the industry, future
revenues, future expenses, future margins, cash usage and financial
performance. For a more detailed discussion of these and associated
risks, see the company's most recent documents filed with the Securities
and Exchange Commission.
